Preparation and Characterization of Zn(II)-Stabilized Aβ42 Oligomers

Alicia González Díaz, Rodrigo Cataldi, Benedetta Mannini, Michele VendruscoloACS 2024 · DOI

TL;DR

Researchers have developed a robust method to stabilize toxic Aβ<sub>42</sub> oligomers using zinc ions, creating a consistent and well-characterized tool for studying Alzheimer's disease. These stabilized oligomers mimic those found in AD brains and exhibit significant cytotoxicity in neuronal cells, paving the way for better understanding AD mechanisms and developing new therapeutics.

What Problem Does This Paper Address?

Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by the accumulation of amyloid-beta (Aβ) peptides in the brain. While Aβ plaques are a hallmark of AD, mounting evidence points to smaller, soluble Aβ oligomers as the primary culprits driving neurotoxicity and cognitive decline. However, these oligomers are notoriously transient and heterogeneous, making them incredibly difficult to isolate, characterize, and study consistently. This lack of well-defined, stable Aβ oligomeric models hinders our understanding of their precise role in AD pathogenesis and the development of effective treatments. This paper aims to address this critical gap by providing a standardized protocol for preparing and characterizing stable Aβ<sub>42</sub> oligomers, specifically using zinc ions (Zn(II)) as a stabilizing agent.

Methods

The core of this work is the development and optimization of a protocol for generating stable Zn(II)-stabilized Aβ<sub>42</sub> oligomers. Building upon a previously established method for Aβ<sub>40</sub>, the researchers adapted it for the more aggregation-prone Aβ<sub>42</sub>. Key modifications included:

  • Peptide Preparation: Aβ<sub>42</sub> monomers were prepared through a rigorous process involving guanidine hydrochloride solubilization, size exclusion chromatography, and lyophilization to ensure purity.
  • Stabilization Reaction Optimization: The protocol involved incubating Aβ<sub>42</sub> monomers with Zn(II) ions under specific conditions. Crucially, they adjusted peptide concentration, buffer composition (using Tris-HCl instead of phosphate to avoid zinc complexation), Zn(II) concentration (increasing the molar excess to 1:10), and reaction volume to minimize air-water interface effects.
  • Oligomer Isolation and Enrichment: After the stabilization reaction, oligomers were isolated via centrifugation. To further enhance stability, the isolated oligomers were resuspended in a buffer enriched with Zn(II).
  • Biophysical Characterization: A suite of techniques was employed to assess the properties of the generated oligomers:
  • SDS-PAGE: To analyze protein distribution in supernatant and pellet fractions.
  • ANS Fluorescence Spectroscopy: To measure the exposure of hydrophobic regions, indicating protein misfolding.
  • Thioflavin T (ThT) Fluorescence Assays: To quantify the presence of β-sheet structures characteristic of amyloid aggregates.
  • Turbidity Measurements: To estimate the average size of the aggregates.
  • ATR-FTIR Spectroscopy: To analyze secondary structures, specifically identifying antiparallel and parallel β-sheet motifs.
  • Dot Blotting: Using conformation-specific antibodies (6E10, A11, OC) to assess reactivity with prefibrillar and fibrillar structures.
  • Transmission Electron Microscopy (TEM): To visualize the morphology, size, and homogeneity of the oligomers.
  • Cellular Toxicity Assays: The cytotoxic effects of the stabilized oligomers were evaluated in human neuroblastoma SH-SY5Y cells by measuring:
  • Reactive Oxygen Species (ROS) Production: Using CellRox dye.
  • Intracellular Calcium Levels: Using Fluo4 dye.
  • Mitochondrial Function: Assessed via MTT assay.

Datasets

Not discussed in the paper. The study focuses on the preparation and characterization of in vitro generated Aβ<sub>42</sub> oligomers.

Key Insights and Ideas

  • Zn(II) as a Powerful Stabilizer: The study confirms and extends the role of Zn(II) in stabilizing Aβ oligomers, demonstrating its effectiveness for the more challenging Aβ<sub>42</sub> peptide. This provides a crucial tool for overcoming the inherent instability of these toxic species.
  • Protocol Optimization is Key: The paper highlights that subtle changes in experimental conditions (buffer, ion concentration, volume) can significantly impact the outcome, emphasizing the need for a standardized, optimized protocol for reproducible results.
  • Homogeneous Oligomeric Species: The optimized protocol yields small (10-30 nm), highly homogeneous, and spherical oligomeric species, a significant improvement over the heterogeneous mixtures often obtained.
  • Distinct Structural Signatures: The Zn(II)-stabilized Aβ<sub>42</sub> oligomers exhibit a unique structural profile, including antiparallel β-sheet structures and reactivity with OC antibodies (characteristic of amyloid aggregates), differentiating them from prefibrillar species.
  • Physiological Relevance: The stabilized oligomers are stable at physiological temperatures and exhibit AD-relevant cytotoxicity, suggesting they are good models for studying disease mechanisms.
  • Cytotoxicity Mechanism: The stabilized oligomers induce dose-dependent increases in ROS production and calcium influx, pointing to mitochondrial dysfunction as a key mechanism of their toxicity.

Key Results

  • A standardized protocol was established for preparing stable Zn(II)-stabilized Aβ<sub>42</sub> oligomers.
  • These oligomers are small (10-30 nm), highly hydrophobic, and possess β-sheet structures.
  • They exhibit a distinct structural profile, including antiparallel β-sheet motifs and reactivity with OC antibodies, but not A11.
  • The stabilized oligomers are stable at 37°C for extended periods.
  • In SH-SY5Y cells, Zn(II)-stabilized Aβ<sub>42</sub> oligomers induced a dose-dependent increase in ROS production and intracellular calcium levels, a response absent in control Aβ<sub>42</sub>.
  • These oligomers also impaired mitochondrial function, as evidenced by reduced MTT levels.

Limitations and Future Work

  • In Vitro vs. In Vivo Stability: While the oligomers are stable in vitro at physiological temperatures, their stability and behavior within a complex cellular environment require further investigation.
  • Single-Molecule Techniques: The authors suggest that advanced nanoscale microscopy techniques (e.g., STORM, PALM) could provide more precise measurements of oligomer size and morphology, and better quantification of their concentrations.
  • Broader Applicability: The protocol's potential for stabilizing oligomers of other amyloidogenic proteins (e.g., hIAPP, α-synuclein, TDP-43) warrants further exploration.
  • Structural Characterization: While FTIR and antibody binding provide insights, further structural characterization using techniques like solid-state NMR and cryo-EM could offer a more complete picture.
  • Therapeutic Development: The authors envision these stabilized oligomers as valuable tools for screening and developing novel AD therapeutics.

Summary updated

Abstract

Aβ oligomers are being investigated as cytotoxic agents in Alzheimer's disease (AD). Because of their transient nature and conformational heterogeneity, the relationship between the structure and activity of these oligomers is still poorly understood. Hence, methods for stabilizing Aβ oligomeric species relevant to AD are needed to uncover the structural determinants of their cytotoxicity. Here, we build on the observation that metal ions and metabolites have been shown to interact with Aβ, influencing its aggregation and stabilizing its oligomeric species. We thus developed a method that uses zinc ions, Zn(II), to stabilize oligomers produced by the 42-residue form of Aβ (Aβ<sub>42</sub>), which is dysregulated in AD. These Aβ<sub>42</sub>-Zn(II) oligomers are small in size, spanning the 10-30 nm range, stable at physiological temperature, and with a broad toxic profile in human neuroblastoma cells. These oligomers offer a tool to study the mechanisms of toxicity of Aβ oligomers in cellular and animal AD models.
BibTeX
@inproceedings{diaz2024preparation,
  author = {Alicia González Díaz and Rodrigo Cataldi and Benedetta Mannini and Michele Vendruscolo},
  title = {{Preparation and Characterization of Zn(II)-Stabilized Aβ<sub>42</sub> Oligomers}},
  booktitle = {ACS},
  year = {2024},
  doi = {10.1021/acschemneuro.4c00084},
}
Figure